Becton, Dickinson and Company (NYSE:BDX) Price Target Raised to $290.00

Becton, Dickinson and Company (NYSE:BDX) had its price objective boosted by equities research analysts at Evercore ISI from $286.00 to $290.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has an “outperform” rating on the medical instruments supplier’s stock. Evercore ISI’s price objective would suggest a potential upside of 20.14% from the company’s current price.

Several other research firms also recently weighed in on BDX. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price target for the stock from $255.00 to $275.00 in a research report on Tuesday. Raymond James reduced their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Finally, Stifel Nicolaus increased their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $282.63.

Becton, Dickinson and Company Price Performance

Shares of BDX stock traded up $0.28 during mid-day trading on Tuesday, hitting $241.38. 583,089 shares of the stock were exchanged, compared to its average volume of 1,420,253. The firm has a fifty day moving average of $236.35 and a 200 day moving average of $235.51. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $269.52. The company has a market cap of $69.76 billion, a PE ratio of 53.10, a price-to-earnings-growth ratio of 1.92 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The business had revenue of $4.99 billion for the quarter, compared to analyst estimates of $5.08 billion. During the same period in the prior year, the company posted $2.96 EPS. The company’s revenue for the quarter was up 2.3% on a year-over-year basis. Research analysts anticipate that Becton, Dickinson and Company will post 13.1 earnings per share for the current year.

Institutional Trading of Becton, Dickinson and Company

Hedge funds and other institutional investors have recently made changes to their positions in the company. Livelsberger Financial Advisory acquired a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth approximately $27,000. OLD Point Trust & Financial Services N A acquired a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth approximately $29,000. Scarborough Advisors LLC acquired a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth approximately $32,000. Rise Advisors LLC acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $38,000. Finally, Opal Wealth Advisors LLC purchased a new position in shares of Becton, Dickinson and Company during the 2nd quarter worth approximately $45,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.